Aliskiren/Amlodipine Single-Pill Combinations: More Evidence in Favour of Combination Formulations for the Treatment of Hypertension

被引：1

作者：

Katsiki, Niki ^{[2
]}

Athyros, Vasilios G. ^{[1
]}

Mikhailidis, Dimitri P. ^{[3
,4
]}

Karagiannis, Asterios ^{[1
]}

机构：

[1] Aristotle Univ Thessaloniki, Propedeut Dept Internal Med 2, Sch Med, Hippocrat Hosp, Thessaloniki 54623, Greece

[2] Agios Dimitrios Gen Hosp, Dept Internal Med 1, Thessaloniki, Greece

[3] UCL, Sch Med, Dept Clin Biochem, Vasc Dis Prevent Clin, London W1N 8AA, England

[4] UCL, Sch Med, Dept Surg, London W1N 8AA, England

来源：

CURRENT VASCULAR PHARMACOLOGY | 2012年 / 10卷 / 06期

关键词：

Aliskiren; amlodipine; single-pill combinations; inadequate blood pressure control; monotherapy; DIRECT RENIN INHIBITOR; ANGIOTENSIN-ALDOSTERONE SYSTEM; HEART-FAILURE; ALISKIREN TRIAL; MANAGEMENT; RATIONALE; DESIGN; LOSARTAN; OUTCOMES; DISEASE;

D O I：

10.2174/157016112803520783

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

In this issue of Curr Vasc Pharmacol, Pfeiffer et al. [1] and Glorioso et al. [2] report the efficacy and tolerability of aliskiren/amlodipine single-pill combinations (SPCs) in patients with inadequate blood pressure (BP) response to amlodipine or aliskiren monotherapy, respectively.

引用

页码：745 / 747

页数：3

共 40 条

[1]

Andersen K, 2009, CLIN INTERV AGING, V4, P137

[2]

Athyros VG, 2010, CURR PHARM DESIGN, V16, P3839, DOI 10.2174/138161210794455085

[3] Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution? [J].

Athyros, Vasilios G. ;

Mikhailidis, Dimitri P. ;

Kakafika, Anna I. ;

Tziomalos, Konstantinos ;

Karagiannis, Asterios .

EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (05) :529-535

[4] Aliskiren in the Management of Hypertension [J].

Barrios, Vivencio ;

Escobar, Carlos .

AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2010, 10 (06) :349-358

[5] What is the risk of hyperkalaemia in heart failure? [J].

Bielecka-Dabrowa, Agata ;

Rysz, Jacek ;

Mikhailidis, Dimitri P. ;

Banach, Maciej .

EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (15) :2329-2338

[6]

Cagnoni F, 2010, VASC HEALTH RISK MAN, V6, P549

[7] Improving Patient Compliance with Hypertension Treatment: Mission Possible? [J].

Chrostowska, Marzena ;

Narkiewicz, Krzysztof .

CURRENT VASCULAR PHARMACOLOGY, 2010, 8 (06) :804-807

[8] Which antihypertensive drugs are the most nephroprotective and why? [J].

Cravedi, Paolo ;

Ruggenenti, Piero ;

Remuzzi, Giuseppe .

EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (16) :2651-2663

[9] Cost-Effectiveness of Aliskiren in Type 2 Diabetes, Hypertension, and Albuminuria [J].

Delea, Thomas E. ;

Sofrygin, Oleg ;

Palmer, James L. ;

Lau, Helen ;

Munk, Veronica C. ;

Sung, Jennifer ;

Charney, Alan ;

Parving, Hans-Henrik ;

Sullivan, Sean D. .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 20 (10) :2205-2213

[10]

Düsing R, 2010, VASC HEALTH RISK MAN, V6, P321

← 1 2 3 4 →